Prof. Dr. med. Peter Fasching



Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction (2024) Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla MK, Abubakar M, et al. Journal article Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (2024) Schmid P, Cortes J, Dent R, Mcarthur H, Pusztai L, Kümmel S, Denkert C, et al. Journal article Smartphone pregnancy apps: systematic analysis of features, scientific guidance, commercialization, and user perception (2024) Nissen M, Huang SY, Jäger K, Flaucher M, Titzmann A, Bleher H, Pontones C, et al. Journal article Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (2024) Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber KE, Rachakonda S, et al. Journal article Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer (2024) Seitz K, Goossens C, Hübner H, Gaß P, Uhrig S, Heindl F, Emons J, et al. Journal article Systematic Comparison of ECG Delineation Algorithm Performance on Smartwatch Data (2024) Jäger K, Nissen M, Flaucher M, Graf L, Joanidopoulos J, Anneken L, Hübner H, et al. Journal article ABC7-Konsens zur Systemtherapie des fortgeschrittenen Mammakarzinoms (2024) Lüftner D, Ditsch N, Fasching P, Busch S, Ettl J, Haidinger R, Jackisch C, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024) Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials (2024) Jank P, Karn T, van Mackelenbergh M, Lindner J, Treue D, Huober J, Engels K, et al. Journal article Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole (2024) Fasching P, Hack C, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al. Journal article